Management of diabetes and other comorbidities is an important therapeutic goal in the treatment of acromegaly (3); while treatment with first-generation somatostatin analogues typically increases FPG levels during the first month of therapy, attainment of disease control (defined in this instance as mean fasting GH ≤2.5 μg/L and normal age- and sex-matched IGF-I) after 12 months of treatment is strongly associated with maintenance of glucose levels or even a reduction in some patients (24). Here, GH1 is linked to diabetes mellitus.